Response to: 'Prognosis of immune-tolerant phase chronic hepatitis B' by Chu and Liaw
- PMID: 29331947
- DOI: 10.1136/gutjnl-2017-315815
Response to: 'Prognosis of immune-tolerant phase chronic hepatitis B' by Chu and Liaw
Keywords: hepatitis b; hepatocellular carcinoma.
Conflict of interest statement
Competing interests: Y-SL is an advisory board member of Bayer HealthCare, Gilead Sciences and Roche and receives research funding from Bayer HealthCare and Gilead Sciences.
Comment on
-
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.Gut. 2018 May;67(5):945-952. doi: 10.1136/gutjnl-2017-314904. Epub 2017 Oct 21. Gut. 2018. PMID: 29055908
-
Prognosis of immune-tolerant phase chronic hepatitis B.Gut. 2018 May;67(5):988. doi: 10.1136/gutjnl-2017-315603. Epub 2017 Nov 25. Gut. 2018. PMID: 29175863 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources